Select Language
DLL3
DLL3 Overview
| English Name | Delta-like protein 3 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 19 | Target Synonym | Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3 |
| Highest Development Stage | Approved | ||
| English Name | Delta-like protein 3 |
| Target Synonym | Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 19 |
| Highest Development Stage | Approved |
DLL3 Product List
- Product Category
Protein (18)Cell (2)Cell Grade Beads (1)Kits (1)
- Product Status
Launched (22)
- Species
Human (15)Cynomolgus (4)Rat (1)Rhesus macaque (1)Mouse (1)
- Tag
His Tag (13)- (5)His Tag & Avi Tag (2)Llama IgG Fc Tag (1)Fc Tag (1)
- Conjugate
Unconjugated (12)FITC Labeled (1)Biotin-labeled (2)PE Labeled (1)- (4)APC Labeled (1)AF647 Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT DL3-H52H4 |  Human | HEK293 | Human DLL3 Protein, His Tag (MALS verified) |  |  |  |
HOT DL3-M52H9 |  Mouse | HEK293 | Mouse DLL3 Protein, His Tag (HPLC verified) | | | |
HOT DL3-C52H3 |  Cynomolgus | HEK293 | Cynomolgus DLL3 Protein, His Tag (MALS verified) |  | | |
CEA-B049 | Human | - | Human DLL3 ELISA Kit | |||
CHEK-ATP090 | Human | HEK293 | HEK293/Human DLL3 Stable Cell Line |  | ||
DL3-H525a | Human | HEK293 | Human DLL3 Protein, Llama IgG2b Fc Tag, low endotoxin |  | | |
DL3-H525c | Human | HEK293 | Human DLL3 (27-215) Protein, Fc Tag (MALS verified) |  | | |
DL3-H52Ha | Human | HEK293 | Human DLL3 (353-492) Protein, His Tag |  | | |
DL3-H52Hy | Human | HEK293 | Human DLL3 (176-492) Protein, His Tag, low endotoxin (MALS & SPR verified) |  | | |
DL3-H52Hz | Human | HEK293 | Human DLL3 (312-492) Protein, His Tag, low endotoxin (SPR verified) |  | | |
Total: 22
- 1
- 2
- 3
DLL3 Background
Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.
DLL3 Synonyms
Delta3,delta-like 3 (Drosophila),delta-like protein 3,DLL3,Pudgy,SCDO1,SCDO1delta3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| MK-6070 | HPN-328; MK-6070 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| SHR-7787 | SHR-7787; SHR7787 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours | Details |
| Obrixtamig | BI-764532; OBT620 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Glioma; Carcinoma, Neuroendocrine | Details |
| Peluntamig | PT-217 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms; Carcinoma, Neuroendocrine | Details |
| ZG006 | ZG006; ZG-006 | Phase 2 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Neuroendocrine | Details |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| IBI-3009 | IBI3009; IBI-3009 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| ALPS-12 | ALPS12; RG6524; RG-6524; ALPS 12 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| SHR-4849 | SHR-4849; SHR4849 | Phase 1 Clinical | Jiangsu Hengrui Pharmaceutical Group Co Ltd | Solid tumours | Details |
| ZL-1310 | ZL-1310; ZL1310; YL212; YL-212 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd, MediLink Therapeutics Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
| FZ-AD005 | FZAD005; FZ-AD005 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg, Boehringer Ingelheim Gmbh | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details | |
| ABD-147 | ABD-147; 225Ac-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Solid tumours; Small Cell Lung Carcinoma; Neuroendocrine Tumors | Details |
| SNC115 | SNC115; SNC-115 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
| QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Small Cell Lung Carcinoma; Neuroendocrine Tumors | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab | AMG-757 | Approved | Amgen Inc | Imdelltra | United States | Small Cell Lung Carcinoma | Amgen Inc | 2024-05-16 | Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Paranasal Sinus Diseases; Carcinoma, Small Cell; Carcinoma, Neuroendocrine; Astrocytoma; Testicular Neoplasms; Carcinoma, Merkel Cell; Medullary thyroid cancer (MTC); Oligodendroglioma; Neuroendocrine Tumors; Urinary Bladder Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Ganglioglioma; Glioblastoma | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main